

| Id | Research Ethics Committee Reference Number | Integrated Research Application System Number | Name of Trial | Target Number Of Patients Agreed? | Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number) | Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number) | Target Date To Recruit Patients Agreed? | Date Agreed to recruit target number of patients | Total Number Of Patients Recruited At The Agreed Target Date | Date That The Trial Closed To Recruitment | Total Number Of Study Participants Recruited | Reason For Closure Of Trial | Comments |
|-------|--|---|---|-----------------------------------|---|---|---|--|--|---|--|-----------------------------|---|
| 41798 | 15/NE/0167 | 171524 | MLN9708 in Multiple Myeloma Not Treated with Stem Cell transplantation - MILLENIUM | Number Agreed | 4 | 4 | Date Agreed | 01/07/2017 | 4 | 19/10/2018 | 4 | Recruitment Finished | |
| 41799 | 18/NE/0200 | 244356 | VX17-445-102 Efficacy and Safety of VX-445/TEZ/IVA in CF Het-min | Number Agreed | 3 | 3 | Date Agreed | 30/06/2019 | 2 | 02/11/2018 | 2 | Withdrawn By Sponsor | Sponsor closed recruitment early. |
| 41800 | 18/NE/0201 | 244419 | VX17-445-103 Efficacy and Safety of VX-445/TEZ/IVA in CF Homozygous | Number Agreed | 3 | 3 | Date Agreed | 31/01/2019 | 2 | 02/11/2018 | 2 | Withdrawn By Sponsor | Sponsor closed recruitment early. |
| 41801 | 18/LO/1002 | 242654 | Study of GSK2857196 in pts. with RRMM who have failed on Daratumumab | Number Agreed | 2 | 2 | Date Agreed | 07/12/2018 | 1 | 19/10/2018 | 1 | Withdrawn By Sponsor | Sponsor closed recruitment early. |
| 41802 | 17/EM/0060 | 215678 | Protocol I1F-MC-RHBY | Number Agreed | 1 | 1 | Date Agreed | 01/01/2019 | 1 | 01/01/2019 | 1 | Recruitment Finished | |
| 41803 | 17/EE/0204 | 207238 | BCX7353 as a treatment for acute HAE attacks | Number Agreed | 3 | 3 | Date Agreed | 01/09/2018 | 4 | 17/10/2018 | 4 | Recruitment Finished | |
| 41804 | 18/NW/0507 | 250276 | A Phase 1/2 Study of VX-121 in Subjects With Cystic Fibrosis and in Subjects without Cystic Fibrosis | Number Agreed | 1 | 1 | Date Agreed | 13/02/2019 | 2 | 13/02/2019 | 2 | Recruitment Finished | |
| 41805 | 17/EE/0074 | 217180 | Lorlatinib (PF-06463922) Open Label Lung Cancer Study | Number Agreed | 2 | 2 | Date Agreed | 31/10/2018 | 1 | 01/02/2019 | 1 | Recruitment Finished | Participants sought, 1 identified within time frame. |
| 41806 | 16/EE/0071 | 193751 | Unravel MGUS | Number Agreed | 100 | 100 | Date Agreed | 01/02/2019 | 66 | 28/02/2019 | 66 | Recruitment Finished | Participants sought, 66 identified within time frame. |
| 41807 | 17/SW/0279 | 231649 | MO39171 - Atezolizumab in locally advanced or metastatic NSCLC | Number Agreed | 6 | 6 | Date Agreed | 30/04/2019 | 4 | 08/11/2018 | 4 | Withdrawn By Sponsor | Sponsor closed recruitment early. |
| 41808 | 18/YH/0069 | 242258 | GLOW study | Number Agreed | 2 | 2 | Date Agreed | 03/03/2019 | 1 | 16/01/2019 | 1 | Withdrawn By Sponsor | Sponsor closed recruitment early. |
| 41809 | 17/LO/1103 | 230709 | Research doses of BAY1817080 in healthy males & PoC in chronic cough pts | Number Agreed | 2 | 2 | Date Agreed | 31/01/2019 | 1 | 31/01/2019 | 1 | Recruitment Finished | Participants sought, 1 identified within time frame, phase 1 study and patients required to come in weekly. |
| 41810 | 18/EM/0228 | 248988 | Anti-viral effect of PC786 on RSV infection in HSCT recipients | Number Agreed | 3 | 3 | Date Agreed | 31/08/2019 | 0 | 08/03/2019 | 0 | Withdrawn By Sponsor | Sponsor closed recruitment early. |
| 41811 | 17/EM/0063 | 213979 | Gilteritinib as Maintenance After Induction/Consolidation in CR1 AML (Astellas AML Maintenance Study) | Number Agreed | 2 | 2 | Date Agreed | 23/05/2019 | 4 | 23/05/2019 | 4 | Recruitment Finished | |
| 41812 | 17/NI/0096 | 225743 | HOPE-1 | Number Agreed | 2 | 2 | Date Agreed | 28/02/2019 | 2 | 22/05/2019 | 2 | Recruitment Finished | |
| 41813 | 17/YH/0369 | 232340 | BGB-3111-304 | Number Agreed | 2 | 2 | Date Agreed | 30/04/2019 | 3 | 09/05/2019 | 3 | Recruitment Finished | |
| 41814 | 17/NI/0128 | 223148 | ALPHA-PE | Number Agreed | 110 | 110 | Date Agreed | 30/03/2018 | 111 | 30/03/2019 | 111 | Recruitment Finished | |
| 41815 | 17/YH/0432 | 236091 | GSK3772847 in participants with Asthma with AFAD | Number Agreed | 3 | 3 | Date Agreed | 28/06/2019 | 1 | 20/06/2019 | 1 | Withdrawn By Sponsor | Sponsor closed recruitment early. |
| 41819 | 15/EE/0442 | 181302 | Phase III Study of AG221 in Late Stage AML with IDH2 mutation | Number Agreed | 2 | 2 | Date Agreed | 28/06/2019 | 0 | 19/10/2018 | 0 | Recruitment Finished | Participants sought, 0 identified within time frame. |
| 41820 | 16/WM/0289 | 204062 | The INSIGHT MM study (NSMM-5001) | Number Agreed | 20 | 20 | Date Agreed | 31/05/2019 | 41 | 03/07/2019 | 41 | Recruitment Finished | Sponsor closed recruitment early. |
| 41821 | 17/LO/0236 | 220765 | PROMINENT | Number Agreed | 13 | 13 | Date Agreed | 31/05/2022 | 0 | 01/08/2019 | 0 | Withdrawn By Sponsor | Sponsor closed recruitment early. |
| 41822 | 18/WM/0132 | 237111 | OPTI-SURF: Optimising surfactant use in neonatal RDS | Number Agreed | 50 | 50 | Date Agreed | 01/02/2021 | 77 | 22/07/2019 | 77 | Withdrawn By Sponsor | Sponsor closed recruitment early. |
| 41823 | 18/LO/1691 | 248968 | INCB-MA-CPCML-402 | Number Agreed | 13 | 13 | Date Agreed | 30/04/2019 | 13 | 22/05/2019 | 13 | Recruitment Finished | |